Loading clinical trials...
Loading clinical trials...
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study to Assess the Efficacy and Safety of MSTT1041A in Patients With Uncontrolled Severe Asthma
Conditions
Interventions
MSTT1041A
Placebo
Locations
138
United States
Alabama Allergy & Asthma
Birmingham, Alabama, United States
Del Sol Research Management
Tucson, Arizona, United States
Kern Allergy Med Clinic, Inc.
Bakersfield, California, United States
Allergy & Asthma Care Center of Southern California
Long Beach, California, United States
CA Allergy & Asthma Med Grp; Medical Group, Inc.
Los Angeles, California, United States
Jonathan Corren MD, Inc.
Los Angeles, California, United States
Start Date
September 20, 2016
Primary Completion Date
April 5, 2019
Completion Date
July 26, 2019
Last Updated
December 28, 2022
NCT07431021
NCT07383896
NCT07282886
NCT06003569
NCT05562466
NCT07486401
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions